Author: Raj, C. T. Dhanya; Kandaswamy, Dinesh Kumar; Danduga, Ravi Chandra Sekhara Reddy; Rajasabapathy, Raju; James, Rathinam Arthur
Title: COVID-19: molecular pathophysiology, genetic evolution and prospective therapeutics—a review Cord-id: a8vj6c3b Document date: 2021_2_8
ID: a8vj6c3b
Snippet: The Covid-19 pandemic is highly contagious and has spread rapidly across the globe. To date there have been no specific treatment options available for this life-threatening disease. During this medical emergency, target-based drug repositioning/repurposing with a continuous monitoring and recording of results is an effective method for the treatment and drug discovery. This review summarizes the recent findings on COVID-19, its genomic organization, molecular evolution through phylogenetic anal
Document: The Covid-19 pandemic is highly contagious and has spread rapidly across the globe. To date there have been no specific treatment options available for this life-threatening disease. During this medical emergency, target-based drug repositioning/repurposing with a continuous monitoring and recording of results is an effective method for the treatment and drug discovery. This review summarizes the recent findings on COVID-19, its genomic organization, molecular evolution through phylogenetic analysis and has recapitulated the drug targets by analyzing the viral molecular machinery as drug targets and repurposing of most frequently used drugs worldwide and their therapeutic applications in COVID-19. Data from solidarity trials have shown that the treatment with Chloroquine, hydroxychloroquine and lopinavir-ritonavir had no effect in reducing the mortality rate and also had adverse side effects. Remdesivir, Favipiravir and Ribavirin might be a safer therapeutic option for COVID-19. Recent clinical trial has revealed that dexamethasone and convalescent plasma treatment can reduce mortality in patients with severe forms of COVID-19.
Search related documents:
Co phrase search for related documents- accessory protein and active site: 1, 2
- accessory protein and acute ards respiratory distress syndrome: 1
- accessory protein structural protein and active site: 1, 2
- accessory structural and acid level: 1
- accessory structural and active site: 1, 2
- accessory structural and acute cardiac injury: 1
- accessory structural protein and active site: 1, 2
- acid level and active form: 1
- acid level and active site: 1, 2
- acid level and acute ards respiratory distress syndrome: 1, 2, 3
- active form and acute ards respiratory distress syndrome: 1
- active site and acute ards respiratory distress syndrome: 1, 2
Co phrase search for related documents, hyperlinks ordered by date